Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life

E. G. Novikova; I. A. Korneyeva; E. A. Ronina; S. A. Shcheltsyna; E. D. Pashanov

doi:10.17650/1994-4098-2010-0-2-53-58

Опухоли женской репродуктивной системы (Aug 2014)

Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life

E. G. Novikova,
I. A. Korneyeva,
E. A. Ronina,
S. A. Shcheltsyna,
E. D. Pashanov

Affiliations

E. G. Novikova: P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
I. A. Korneyeva: P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
E. A. Ronina: P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
S. A. Shcheltsyna: P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
E. D. Pashanov: Medical Department, GlaxoSmithKline, Moscow

DOI: https://doi.org/10.17650/1994-4098-2010-0-2-53-58
Journal volume & issue: Vol. 0, no. 2
pp. 53 – 58

Abstract

Read online

The main goals of the study were to evaluate the efficacy and safety of intravenous topotecan (Hycamtin) used in a dose of 4 mg/m2 on days 1, 8, and 15 of a 28-day course of therapy in patients with recurrent ovarian cancer. The study revealed a number of benefits from use of topotecan in patients with this diagnosis.

Published in Опухоли женской репродуктивной системы

ISSN: 1994-4098 (Print); 1999-8627 (Online)
Publisher: ABV-press
Country of publisher: Russian Federation
LCC subjects: Medicine: Gynecology and obstetrics
Website: http://ojrs.abvpress.ru/

About the journal

Abstract

Keywords